Quarterly Outlook
Equity outlook: The high cost of global fragmentation for US portfolios
Charu Chanana
Chief Investment Strategist
Investor Content Strategist
Man Utd stock falls after club loses Europa League final
Club to miss out on £100mn revenues from Champions League participation
Highlights risks of binary-outcome investing
This content is marketing material. This article is not investment advice, capital is at risk.
Manchester United stock fell sharply after the club lost the Europa League final to Tottenham. It means missing out on a lucrative entry to the Champions League next season, which would have generated up to £100 million from tickets, broadcast money, and sponsor bonuses.
That’s £100mn on the outcome of one match. For a club that has chalked up £370mn in losses in the last five year and little in the way of silverware, it’s a big blow to its financial outlook.
It also highlights some risks investors face when betting on a binary outcome like a game of football.
Investing in assets where the outcome hinges on a single binary event—success or failure—is inherently high risk. These are situations where one pivotal development determines the majority of a company’s value, such as an oil explorer striking a commercially viable well or a pharmaceutical company gaining (or being denied) FDA approval for a new drug. The outcome is often binary: a “yes” or “no,” and the market reaction can be extreme in either direction. While the rewards can be substantial, the risks are equally severe.
Binary-outcome investments are essentially bets on a single future event. If the event resolves positively, the stock can surge—sometimes by several multiples. If it fails, the value can collapse, sometimes to near-zero. These outcomes are driven by asymmetric information, long lead times, and uncertainty around technical, regulatory, or commercial success.
This type of investing is more akin to speculation than traditional investing, which typically involves diversified portfolios and fundamental valuation. Binary investments have unpredictable payoff structures, and standard valuation metrics (like price-to-earnings ratios or cash flow projections) are often meaningless until after the outcome is known.
Pharmaceuticals and FDA Approval: One of the most prominent examples is the biotech sector. A small-cap biotech firm developing a new cancer drug may spend years and hundreds of millions in R&D, but its entire valuation can ride on a single clinical trial or regulatory decision. For example, Biogen’s stock experienced extreme market reactions tied to the FDA decision on its Alzheimer’s drug Aduhelm —surging on approval and facing backlash and volatility after commercial uptake disappointed.
Oil and Gas Exploration: Junior oil exploration firms often trade at low valuations until they drill. A single well can either unlock a lucrative new basin or reveal nothing. For instance, shares in exploration companies operating off the coast of Namibia or in the North Sea have shown 80–90% price swings based on drill results. The capital-intensive nature of exploration and the lack of revenue until discovery amplify the risk.
Litigation and Binary Legal Risks: Some companies—especially in industries like tobacco, tech, or crypto—face binary risks linked to legal judgments or regulatory changes. A ruling against a firm in a key patent dispute or anti-trust case can instantly destroy value. Meta’s stock, for example, has been heavily impacted by rulings around privacy and data collection. Investing in UnitedHealth right now is another example where the future is contingent on legal cases.
Another example hitting the headlines right now is quantum computing – no one knows whether these bets in some early-stage pure-play quantum computing stocks will pay off in the long term.
The allure of a ten-bagger—stocks that rise tenfold—can entice retail and institutional investors alike into high-stakes bets. Often, investors underestimate the likelihood of failure or overestimate their ability to assess complex risks. Market hype, selective information disclosure, and behavioral biases such as optimism and confirmation bias only compound the problem.
Additionally, binary-outcome companies often raise capital through dilutive equity issuance, making long-term shareholder value even more precarious. Investors betting on a positive outcome may find themselves heavily diluted or facing a capital crunch if the binary event doesn’t go in their favour.
Investors can mitigate exposure to binary-outcome risk through diversification, position sizing, and scenario analysis. Where appropriate, they might also use options to define risk more tightly. Ultimately, such investments should be treated as speculative side bets rather than core holdings in a long-term portfolio.
Binary-outcome investing offers high-stakes drama—and sometimes high rewards—but carries the real risk of total loss. Understanding the nature of these bets, and allocating capital accordingly, is essential for any disciplined investor.
Enjoy this article?
Refer a friend and earn £500 commission credits
Refer a friend to Investor Refer a friend to TraderGO
Introduce a friend to Saxo, and you'll both receive commission credits for future trades